Interleukin (IL)-11 is a member of the IL-6 family of cytokines and is involved in multiple cellular responses, including tumor development. However, the origin and functions of IL-11-producing (IL-11+) cells are not fully understood. To characterize IL-11+ cells in vivo, we generate Il11 reporter mice. IL-11+ cells appear in the colon in murine tumor and acute colitis models. Il11ra1 or Il11 deletion attenuates the development of colitis-associated colorectal cancer. IL-11+ cells express fibroblast markers and genes associated with cell proliferation and tissue repair. IL-11 induces the activation of colonic fibroblasts and epithelial cells through phosphorylation of STAT3. Human cancer database analysis reveals that the expression of genes enriched in IL-11+ fibroblasts is elevated in human colorectal cancer and correlated with reduced recurrence-free survival. IL-11+ fibroblasts activate both tumor cells and fibroblasts via secretion of IL-11, thereby constituting a feed-forward loop between tumor cells and fibroblasts in the tumor microenvironment.
Maintenance of intestinal homeostasis involves a variety of cell types, including epithelial, immune, and stromal cells1,2,3. Within the intestinal lamina propria, stromal cells include fibroblasts, α-smooth muscle actin (αSMA)-positive myofibroblasts, endothelial cells, and pericytes4,5. These stromal cells organize the tissue architecture and have recently been revealed to play crucial roles in regulating immune responses, tissue repair, and tumor development3,4,5. Recent studies have focused on fibroblasts that can support tumor growth, termed cancer-associated fibroblasts (CAFs)6,7,8. In a recent study, single-cell RNA sequencing (scRNA-seq) was performed to analyze colon biopsies from healthy individuals and ulcerative colitis (UC) patients. The results revealed that UC patients’ colon samples include a unique subset of fibroblasts, termed inflammation-associated fibroblasts (IAFs), with high expression of Interleukin 11 (IL11), IL24, IL13RA2, and TNFSFR11B9. Another study reported that constitutive STAT3 activation in collagen VI (ColVI)-expressing fibroblasts enhances azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced colitis-associated colorectal cancer (CAC) in mice10. Conversely, deletion of Stat3 in ColVI+ fibroblasts attenuates the development of CAC. Together, these findings suggest that stromal fibroblasts may constitute different cell populations and play a crucial role in the development of cancer and colitis, but the full picture of fibroblast heterogeneity and function remains unclear.
IL-11 is a multifunctional member of the IL-6 family, contributing to hematopoiesis, bone development, tissue repair, and tumor development11,12. The IL-11 receptor comprises IL-11Rα1, which binds IL-11, and gp130, which transmits signals to the nucleus via Janus kinase (JAK) activation13. JAKs phosphorylate STAT3, and phosphorylated STAT3 enters the nucleus where it activates the transcription of various target genes associated with cell proliferation and cell survival14,15,16,17. IL-11 production is regulated by several cytokines, including TGFβ, IL-1β, IL-17A, and IL-2218,19,20,21. We have previously demonstrated that IL-11 production is induced by reactive oxygen species (ROS) and the electrophile 1,2-naphthoquinone. This, in turn, promotes liver and intestine tissue repair22,23. While IL-11 is reportedly produced in various cell types (including stromal, hematopoietic, and epithelial cells) in response to different stimuli16,17,24,25, the cellular sources of IL-11 in vivo are not fully understood.
TGFβ expression is frequently elevated in human CRC and is correlated with a high risk of tumor recurrence24. Tumor-derived TGFβ induces Il11 expression in stromal fibroblasts in a paracrine manner, whereas enforced expression of TGFβ in tumor cells promotes metastasis in tumor xenograft model24. Moreover, TGFβ induces expression of a long noncoding RNA activated by TGFβ (LncRNA-ATB), which subsequently elevates IL-11 production by stabilizing Il11 mRNA in tumor cells26. Consistently, IL-11 expression is elevated in CRCs in humans and mice10,17,24,27. Repeated injection of IL-11 results in an increase in the number and size of colorectal tumors in AOM/DSS-treated mice10. Conversely, deletion of the Il11ra1 gene attenuates CAC development in mice treated with AOM/DSS or in adenomatous polyps of mice harboring a mutation in the Adenomatous polyposis coli (Apc) gene (ApcMin/+)17. Together, these results suggest there is intimate crosstalk between TGFβ and IL-11 and that TGFβ-induced tumor promotion is mediated, at least in part, by IL-11. Moreover, recent studies have reported that IL-11 plays a crucial role in fibrosis development in various organs, including the lung, heart, liver, and kidney28,29.
In this study, we aim to characterize IL-11-producing cells in vivo. We generate Il11-Enhanced green fluorescence protein (Egfp) reporter mice and detect IL-11+ cells in the colonic tumor tissues of a CAC mouse model and ApcMin/+ mice. Deletion of Il11ra or Il11 attenuates CAC development in mice. When tumor organoids are transplanted into the colon, IL-11+ cells appear in the tumor tissues. Moreover, IL-11+ cells rapidly appear in mouse colon after DSS treatment. IL-11+ cells express stromal cell markers and genes associated with cell proliferation and tissue repair, suggestive of colonic fibroblasts. IL-11 induces robust STAT3 phosphorylation in both colonic fibroblasts and colon epithelial organoids. Using the human cancer database, we find that the expression of some genes with enriched expression in IL-11+ fibroblasts is also elevated in human CRC and that high expression of a set of these genes is correlated with reduced recurrence-free survival in CRC patients. Together, our present results demonstrate that tumor cells induce IL-11+ fibroblasts and that a feed-forward loop between colon tumor epithelial cells and IL-11+ fibroblasts via secretion of IL-11 may contribute to tumor development.
Characterization of IL-11+ cells in CAC using Il11-Egfp reporter mice
To characterize IL-11-producing (IL-11+) cells in vivo, we generated transgenic mice in which Egfp expression was under the control of the Il11 gene promoter, using a bacterial artificial chromosome (BAC) vector (Supplementary Fig. 1a). An Egfp cDNA and a polyA signal were inserted in-frame in the second exon of the Il11 gene (Supplementary Fig. 1a). As expected, Il11 mRNA expression was correlated with Egfp mRNA expression in various tissues (Supplementary Fig. 1b, c). Notably, Il11 mRNA expression was highest in the testis and was very low in other mouse tissues under normal conditions (Supplementary Fig. 1b).
Although Il11 mRNA expression is elevated in CRC in mice and humans16,17, cellular sources of IL-11 remain controversial. We used Il11-Egfp reporter mice to monitor the appearance of IL-11+ cells in a CAC model. AOM administration followed by repeated exposure to DSS causes CAC development in mice30,31. On day 77 after AOM/DSS administration, the Il11-Egfp reporter mice developed large tumors in the colon (Fig. 1a, b). We isolated tumor and nontumor tissues and examined Il11 mRNA expression using qPCR. Il11 and Egfp mRNA expression was elevated in tumor tissues compared with nontumor tissues from mice with AOM/DSS-induced CAC (Fig. 1c).
We next isolated and characterized IL-11+ cells from tumors of Il11-Egfp reporter mice. We observed that the percentage of cells that were EGFP (IL-11)+ was increased in tumor tissues compared with nontumor colon tissues from AOM/DSS-treated Il11-Egfp reporter mice (Fig. 1d, Supplementary Fig. 1d). The majority of IL-11+ cells expressed mesenchymal stromal cell markers, such as Thy1.2, podoplanin, CD29, and Sca-1, but not CD31 or Lyve-1, whereas only very small percentages of IL-11+ cells expressed EpCAM (Fig. 1e). Conversely, only 5% of podoplanin+ cells (mostly fibroblasts) expressed IL-11 (Fig. 1f). Immunohistochemistry (IHC) revealed that IL-11+ cells appeared in the stroma surrounding tumor cells (Fig. 1g). Of note, we could not detect EGFP+ cells in the colon of Il11-Egfp reporter mice before AOM/DSS treatment, or wild-type mice even after AOM/DSS treatment (Supplementary Fig. 1e), suggesting that GFP signals did not reflect the autofluorescence of the tissues. We found that most IL-11+ cells also expressed GFP (Fig. 1h, i), further substantiating Il11-Egfp reporter mice indeed monitored endogenous IL-11+ cells. IL-11+ cells also expressed vimentin, collagen I, and collagen IV, but not αSMA (Supplementary Fig. 1f), suggesting that these cells were fibroblasts but not myofibroblasts. Consistent with the flow cytometry results (Fig. 1f), a few E-cadherin-positive tumor cells were positive for EGFP expression (Fig. 1j). Overall, these results suggest that most IL-11+ cells were stromal fibroblasts, but few IL-11+ cells were colonic epithelial cells.
Expression of Il11 in colons from untreated mice was lower than that in colon tumor tissues from AOM/DSS-treated mice (0.002 in normal colon vs. 0.05 in tumor tissues) (Supplementary Fig. 1b, Fig. 1c). These results suggest that small numbers of resident IL-11+ cells might proliferate and expand in situ; alternatively, IL-11− cells could be converted into IL-11+ cells after AOM/DSS treatment. Another possibility is that IL-11+ cells are recruited to the colon from other tissues. To discriminate among these three possibilities, we investigated whether IL-11+ cells expressed the cell-proliferating antigen Ki67. We quantified percentages of Ki67+ and podoplanin+ cells among EGFP+ cell populations in nontumor and tumor tissues. We could not detect EGFP+ cells in nontumor tissues (Fig. 1k, upper panels). Consistent with the flow cytometry results, most EGFP+ cells expressed podoplanin, while only 4% of EGFP+ cells expressed Ki67 (Fig. 1k lower panels, and Fig. 1l).
We also examined the possibility that IL-11+ cells were derived from bone marrow (BM). We transferred BM cells from Il11-Egfp reporter mice to lethally irradiated wild-type mice. One month following reconstitution, Il11-Egfp BM chimeric mice were treated with AOM/DSS to induce colorectal tumors (Supplementary Fig. 1g). Although the expression of Il11 was elevated in tumor tissues compared with non-tumor tissues, the Egfp expression that can represent Il11 expression in BM-derived cells was not elevated in either tumor tissues or non-tumor tissues from Il11-Egfp BM chimeric mice (Supplementary Fig. 1h). Notably, cells expressing both EGFP and IL-11 were easily detected in colon tumor tissues of AOM/DSS-treated Il11-Egfp reporter mice (Fig. 1h, i). In contrast, only IL-11+ and not EGFP+ cells were detected in the colon tumor tissues of AOM/DSS-treated Il11-Egfp BM chimeric mice (Supplementary Fig. 1i). Together, these results suggest that most IL-11+ cells are not likely derived from BM cells, but that IL-11− cells became IL-11+ cells during tumor development. We refer to IL-11+ cells as IL-11+ fibroblasts hereafter.
Attenuated CAC development in Il11ra1 −/− and Il11 −/− mice
A previous study reported attenuated CAC development in Il11ra1−/− mice17. Our present data consistently confirmed the attenuation of AOM/DSS-induced CAC in Il11ra1−/− mice compared with wild-type mice (Supplementary Fig. 2a). To further substantiate that the IL-11/IL-11R-dependent signaling pathway contributed to CAC development, we investigated Il11−/− mice. As we previously reported32, Il11−/− mice showed no abnormalities. When wild-type and Il11−/− mice were treated with AOM/DSS, we observed attenuated CAC development in Il11−/− mice compared with wild-type mice (Supplementary Fig. 2b). Moreover, reciprocal BM transfer experiments revealed that Il11 expression in non-hematopoietic cells might be primarily responsible for the increased tumor numbers and tumor load in the colon (Supplementary Fig. 2c, d). We focused our subsequent analyses on IL-11+ fibroblasts.
IL-11+ fibroblasts appear in tumor tissues in the absence of colitis
The above-described results suggested that IL-11- cells might cell-autonomously become IL-11+ cells in the colonic tissues within the inflammatory milieu or in tumors triggered by AOM/DSS. We used two different colitis-independent murine tumor models to discriminate between these possibilities: adenomatous polyps in ApcMin/+ mice33 and tumor organoids transplanted into wild-type mice. To monitor IL-11+ cells, we crossed ApcMin/+ mice with Il11-Egfp reporter mice. In ApcMin/+ mice, Il11 and Egfp mRNA expression levels were elevated in colon tumors compared with nontumor tissues (Fig. 2a), and IL-11+ cells appeared in the stroma surrounding tumor cells in the colon (Fig. 2b). Consistent with the IHC results, we found increased percentages of IL-11+ cells in the tumor tissues compared with non-tumor colon tissues from ApcMin/+;Il11-Egfp reporter mice by flow cytometry (Fig. 2c). Most IL-11+ cells expressed podoplanin and Thy1.2, and small numbers of IL-11+ cells expressed epithelial cell markers (Fig. 2d). Hence, the majority of IL-11+ cells were fibroblasts. Of note, EGFP+ cells only appeared in the colon tumors of ApcMin/+;Il11-Egfp reporter mice, but not ApcMin/+ mice (Supplementary Fig. 3a), indicating that EGFP signals in ApcMin/+;Il11-Egfp reporter mice did not likely reflect the autofluorescence, but represented specific signals of IL-11. Again, we observed weak EGFP expression in some E-cadherin-positive tumor cells themselves (Fig. 2e). Only 4% of IL-11+ fibroblasts were positive for Ki67+ (Fig. 2f, g). IL-11+ fibroblasts expressed vimentin, collagen I, and collagen IV, but not αSMA (Fig. 2h). We also found that the expression levels of Il11 and Egfp were elevated in the tumor tissues compared with non-tumor tissues in small intestine from ApcMin/+;Il11-Egfp reporter mice, and IHC revealed that IL-11+ fibroblasts appeared in the tumor tissues (Supplementary Fig. 3b, c). Moreover, consistent with the results from Apcmin/+;Il11ra1−/− mice17, deletion of Il11 attenuated the development of tumors in the colon and small intestine of Apcmin/+ mice (Fig. 2i, j).
We previously generated tumor organoids from the intestines of AKTP mice; these exhibit mutations in Apc, Kras, Tgfbr2, and Tp53 in intestinal epithelial cells34. These tumor organoids were transplanted into the colons of Il11-Egfp reporter mice, and we examined whether IL-11+ fibroblasts appeared along with tumor development (Supplementary Fig. 4a). On day 30 post-transplantation, the tumor organoids developed large tumors and destroyed normal epithelial tissues in the colon (Supplementary Fig. 4b). Importantly, IL-11+ fibroblasts appeared in the tumor tissues (Supplementary Fig. 4c). These IL-11+ fibroblasts expressed podoplanin and vimentin, but not CD45 or E-cadherin (Supplementary Fig. 4d). Together, these results are strong evidence that IL-11− cells became IL-11+ cells; alternatively, IL-11+ cells could have been recruited to tumor tissues in the absence of colitis.
To detect the interplay between IL-11+ fibroblasts and colon tumor cells, we tested whether IL-11 induced the activation of colon tumor cells. IL-11 stimulation-induced phosphorylation of STAT3 in AKTP tumor organoids and human colon cancer cell lines (Supplementary Fig. 4e). We also found that IL-11 induced both STAT3 and ERK activation in colonic fibroblasts (Supplementary Fig. 4e). These results suggest that IL-11 induces activation signals in colon tumor cells and fibroblasts.
IL-11+ fibroblasts appear in the colon in DSS-treated mice and express stromal cell markers
To determine whether colitis alone induces IL-11 expression, we treated Il11-Egfp reporter mice with only DSS. Il11 expression in the colon was very low in untreated wild-type mice, but gradually increased and peaked on day 7 after DSS treatment (Fig. 3a). IHC revealed that on day 8 after DSS treatment, many IL-11+ cells appeared in the subepithelial tissues, where intestinal epithelial cells were detached due to severe inflammation (Fig. 3b). We detected the rapid appearance of IL-11+ cells just 1 day after DSS treatment (Fig. 3c). Consistently, small numbers of IL-11+ cells rapidly appeared in the colon on day 1 and they had increased as a percentage of all cells on day 7 after DSS treatment (Fig. 3d, e). For a more detailed comparison of the phenotypes of IL-11+ fibroblasts in tumor tissues and the IL-11+ cells that appeared in colitis, we also analyzed the expression of various cell surface markers in the latter. These IL-11+ cells expressed stromal cell markers, including Thy1.2, podoplanin, CD29, ICAM-1, VCAM-1, and Sca-1, but not CD45.2, CD31, EpCAM, Lyve1, or Ter119 (Fig. 3f). IL-11+ cells associated with colitis were also positive for vimentin, collagen I, and collagen IV, but not αSMA (Fig. 3g), suggesting that these cells were fibroblasts, but not myofibroblasts. Moreover, very few of these IL-11+ fibroblasts incorporated 5-bromo-2ʹ-deoxyuridine (BrdU), a hallmark of cell proliferation, suggesting that most of them did not proliferate in situ (Fig. 3h, i). Together, these findings suggest that colitis alone was sufficient to induce Il11 expression in fibroblasts.
IL-11+ fibroblasts express genes associated with cell proliferation and tissue repair
To further characterize the IL-11+ fibroblasts that appeared in colitis, we used a cell sorter to isolate EGFP+ and EGFP− fibroblasts from the colons of DSS-treated Il11-Egfp reporter mice and compared their gene expression profiles using RNA-seq (Supplementary Fig. 5a). We confirmed that sorted IL-11+ and IL-11− cells exhibited high and low expression, respectively, of Il11 and Egfp (Fig. 4a). A volcano plot showed significantly elevated expression of some genes in IL-11+ fibroblasts compared with IL-11− fibroblasts (Fig. 4b). Gene ontology (GO) enrichment analysis revealed that EGFP+ cell RNA was enriched in transcripts of genes associated with cell proliferation, angiogenesis, and wound healing (Fig. 4c). The expression levels of a cytokine, cytokine receptor, and chemokine (Il11, Il1rl1, and Cxcl5), and of genes associated with organ development (Hgf and Tnfsf11), were elevated in IL-11+ fibroblasts (Fig. 4d). Moreover, transcript levels of genes associated with CRC susceptibility loci (e.g., Grem1 and Bmp4) and tumor development and invasion (e.g., Wnt5a, Ereg, Mmp3, Mmp13, Timp1, Saa3, Ptgs2, and Acsl4) were elevated in IL-11+ fibroblasts (Fig. 4d). Of note, expression of Il11ra1 (encoding IL-11 receptor) was not different between IL-11+ and IL-11− fibroblasts (Fig. 4e), suggesting that IL-11 can induce signals in both IL-11+ and IL-11- fibroblasts.
A unique subset of fibroblasts termed IAFs has recently been reported in UC patients9. To investigate the relationship between IL-11+ fibroblasts and IAFs, we examined their gene expression. We found elevated expression of Il13ra2 and Tnfsfr11b (markers of IAFs) in IL-11+ fibroblasts compared with IL-11− fibroblasts (Fig. 4d). However, gene set enrichment analysis revealed that the global gene expression profiles of IL-11+ fibroblasts and IAFs were different (Fig. 4f), suggesting that IL-11+ fibroblasts and IAFs are not identical, but rather different cell populations.
To test whether fibroblasts with gene signatures similar to that of IL-11+ fibroblasts appear in tumor tissues in mouse and human colon cancers, we examined gene expression profiles of tumor tissues. We found that the expression levels of some genes enriched in IL-11+ fibroblasts, including Wnt5a, Mmp13, Timp1, Il1rl1, Cxcl5, Saa3, Inhiba, Ascl4, and Tnfrsf11b, were elevated in mouse AOM/DSS-induced colon tumor tissues (Supplementary Fig. 5b). IHC also confirmed that IL-11+ fibroblasts expressed Wnt5a in colons affected by DSS-induced colitis and colon tumor tissues from AOM/DSS-treated mice (Supplementary Fig. 5c). Collectively, the gene expression profiles of IL-11+ fibroblasts present in DSS-induced colitis may at least partly overlap those of colon tumors in mice treated with AOM/DSS.
The MEK/ERK pathway is involved in Il11 upregulation in the colon in DSS-treated mice
Since IL-11+ fibroblasts might promote tumor development, it is crucial to investigate the mechanisms by which acute inflammation or tumor cells induce IL-11 expression. Several studies have reported that TGFβ induces IL-11 production in various cells20,21,24. Indeed, TGFβ strongly induced IL-11 production by colonic fibroblasts (Supplementary Fig. 6a). However, expression of Tgfb1-3 was not elevated in colon from DSS-treated mice (Supplementary Fig. 6b), and neutralizing antibody against TGFβ did not block Il11 expression in the colon (Supplementary Fig. 6c). These results suggest that TGFβ is not responsible for Il11 expression in DSS-induced colitis.
We previously reported that oxidative stress induces Il11 mRNA expression in an ERK/Fra-1-dependent manner22,23. Thus, we tested whether DSS treatment-induced oxidative stress in the colon. We observed enhanced oxidative stress in colonic cells after DSS treatment and found that administration of an antioxidant, N-acetyl cysteine (NAC), attenuated this DSS-induced oxidative stress (Fig. 5a). In addition, DSS-induced oxidative stress was ameliorated by administering antibiotics (Abx) (Fig. 5b), suggesting that bacterial infection induces oxidative stress. Consistent with these findings, both an antioxidant, NAC, and Abx blocked the DSS-induced upregulation of Il11 mRNA (Fig. 5c, d). Furthermore, DSS-induced ERK phosphorylation was blocked by the MEK inhibitor trametinib and accompanied by downregulation of Il11 expression (Fig. 5e–g). We also found that NAC treatment reduced pERK+ areas (Fig. 5h, i). These results indicate that oxidative stress-dependent ERK activation might contribute to Il11 expression in the colon.
Blockade of the MEK/ERK pathway reduces proliferation and induces apoptosis in tumor tissues of AOM/DSS-treated mice
We next investigated whether Il11 expression was induced in the tumor microenvironment in a manner similar to that in DSS-induced colitis. Consistent with the results of DSS-induced colitis, the expression of Tgfb1-3 was not elevated in the colon in AOM/DSS-treated mice and ApcMin/+ mice, and anti-TGFβ antibody did not reduce the expression of Il11 in colon tumor tissues in these mice (Supplementary Fig. 7a–f). Of note, administration of trametinib, but not Abx or NAC, reduced Il11 expression in CAC after AOM/DSS treatment (Fig. 6a–d). Intriguingly, trametinib reduced the percentage of Ki67+ proliferating cells, and conversely, increased the percentage of cleaved caspase 3 (CC3)+ cells (a hallmark of apoptosis) (Fig. 6e, f).
Blockade of the MEK/ERK pathway reduces proliferation and induces apoptosis in tumor tissues of Apc Min/+ mice
We observed a similar inhibitory effect of trametinib, but not Abx or NAC, on colon tumors in ApcMin/+ mice (Fig. 7a–d). Consistent with colon tumors in AOM/DSS-treated mice, trametinib treatment decreased the percentage of Ki67+ cells and, conversely, increased the percentage of CC3+ cells (Fig. 7e, f). We also found similar effects of trametinib on tumors of the small intestine in ApcMin/+ mice, although the decrease in Il11 expression in response to trametinib was not statistically significant (Fig. 7g–i). Together, these results suggest that Il11 expression was induced in a MEK/ERK-dependent manner, although the upstream signals that induce activation of the MEK/ERK pathway could differ between colitis and tumors.
IL-11 induces signals in colonic epithelial cells and fibroblasts
Previous studies report that IL-11 induces signals in colonic epithelial cells and fibroblasts17,29. We first examined the Il11ra1 expression on colonic fibroblasts and normal colon organoids. Since IL-22 induces signals in intestinal epithelial cells35, we also examined the IL-22 receptor expression on both cell types. Colon organoids showed high expression of Il22ra, but not Il11ra, while colon fibroblasts exhibited high expression of Il11ra and Il6st (encoding gp130), but not Il22ra (Fig. 8a). Consistently, while IL-11 stimulation-induced STAT3 phosphorylation in colon fibroblasts, and to a lesser extent in colon organoids, IL-22 preferentially induced STAT3 phosphorylation in colon organoids (Fig. 8b). IL-11 stimulation-induced STAT3 phosphorylation in AKTP tumor organoids and human tumor cell lines (Supplementary Fig. 4e), prompting us to compare the signals induced by IL-11 in normal colon and tumor organoids. We prepared colon organoids from WT and Apcdelta716 mice carrying a truncated Apc gene (Apcdelta716)36. Intriguingly, the expression of Il11ra and Il6st was higher in Apcdelta716 colon organoids than in WT colon organoids (Fig. 8c). Consistent with the expression levels of Il11ra, IL-11 strongly induced STAT3 phosphorylation in Apcdelta716 colon organoids and, to a lesser extent, WT colon organoids (Fig. 8d). Moreover, IL-11 stimulation-induced ERK phosphorylation in WT and Apcdelta716 colon organoids. Together, Il11ra expression in colonic epithelial cells increased along with tumor development, thereby enabling colon tumor cells to respond to IL-11 stimulation efficiently.
To test whether IL-11 stimulation contributes to the upregulation of enriched genes in IL-11+ fibroblasts in a paracrine or autocrine manner, we injected an IL-11R agonist manipulated to increase the stability and biological activity of human IL-11 into wild-type mice22. As expected, IL-11R agonist injection resulted in the upregulation of many genes in the whole colon from wild-type mice (Fig. 8e). Some of these genes were enriched in IL-11+ fibroblasts (Fig. 8f). We performed qPCR to verify the induction of these genes in the whole colon after injection of the IL-11R agonist (Supplementary Fig. 8). These results suggest that IL-11, at least in part, activates IL-11+ fibroblasts in an autocrine or paracrine manner, but other signals may induce the majority of enriched genes in IL-11+ fibroblasts.
A recent study reported that ColVI+ fibroblasts critically contribute to the development of CAC10. It also analyzed gene expression profiles in ColVI+ fibroblasts stimulated with IL-6 or IL-11. We tested whether IL-11 stimulation-induced gene expression patterns in ColVI+ fibroblasts similar to those in IL-11+ fibroblasts. However, most enriched genes in IL-11+ fibroblasts were different from those in IL-11-stimulated ColVI+ fibroblasts (Fig. 8g), suggesting that these two fibroblasts constitute different cell populations or represent different stages of activation.
IL-11 expression is correlated with the progression of human cancers
To characterize IL-11+ cells in human colon tumor samples, we collected human tumor samples (Supplementary Table 1), including adenoma and early and advanced CRC for IHC with anti-human IL-11 antibody. First, we verified that anti-human IL-11 antibody detected endogenous IL-11, using lysates of the human breast cancer cell line MDA-MB-231 that constitutively produce IL-1137, in the presence of control or human Il11 siRNAs (Supplementary Fig. 9a). IL-11+ cells were scarce in normal colonic tissues but were numerous in adenomas and in early and advanced CRC tissues (Fig. 9a). In contrast, advanced CRC tissues were not stained with control IgG (Supplementary Fig. 9b), suggesting that anti-IL-11 antibody staining did not represent background tissue signals. Intriguingly, the relative area of IL-11+ cells and the IL-11 signaling intensity were increased in the stroma of advanced colon cancers compared with normal tissues (Fig. 9b, c), suggesting an intimate correlation between IL-11+ fibroblasts and CRC progression.
Some genes enriched in IL-11+ fibroblasts is correlated with reduced recurrence disease-free durations in human CRC
Assuming that the appearance of IL-11+ fibroblasts was correlated with CAC development in mice and humans (Figs. 1, 2 and 9), we hypothesized that the genes enriched in IL-11+ fibroblasts might also be elevated in human CRC. We focused on genes with over twofold greater expression in IL-11+ fibroblasts compared with IL-11− fibroblasts (Fig. 4), and extracted 22 genes matching our criteria from the human cancer databases (GSE33133 and GSE35602). Intriguingly, most but not all subsets of genes elevated in IL-11+ fibroblasts were significantly upregulated in colon cancer tissues relative to normal mucosa (Fig. 10a). Moreover, analysis using the human CRC database (GSE35602) revealed that the expression of some genes with high expression in IL-11+ fibroblasts was also elevated in tumor stromal compartments compared with tumor epithelial compartments (Supplementary Fig. 10).
Since many of the genes enriched in IL-11+ fibroblasts were also upregulated in tumor tissues (Fig. 10a and Supplementary Fig. 5a), we hypothesized that the genes with elevated expression in IL-11+ fibroblasts might critically affect the prognosis of cancer patients. Using human CRC datasets (GSE17536, GSE17537, and GSE14333), we first divided patients into two clusters based on the expression of IL11 or signature genes of IAFs (IL11/IL24/IL13RA2/TNFRSR11B) by the hierarchical clustering method. However, neither clusters did not result in any differences in recurrence-free survival durations (Fig. 10b, c). We next divided patients based on the expression patterns of genes preferentially expressed in IL-11+ fibroblasts (twofold higher than IL-11− fibroblasts), which we referred to as the IL-11+ fibroblast signature (IL11FS). Intriguingly, recurrence-free survival durations were significantly decreased in cluster 6 compared with cluster 5 (Fig. 10d). Given that the expression of a set of genes including HGF, IL13RA2, PTGS2, and TNFSF11 in cluster 6 was higher than in cluster 5 (Supplementary Data 1), these upregulated genes may be associated with poor CRC prognosis.
In this study, we generated Il11-Egfp reporter mice to characterize IL-11+ cells in different murine tumor and colitis models. We found that the IL-11+ cells in tumor tissues were mostly fibroblasts and a few epithelial cells and that deletion of Il11ra or Il11 attenuated CAC development in mice. BM transfer experiments revealed that IL-11+ fibroblasts critically contributed to tumor progression and that IL-11+ fibroblasts were not derived from BM. IL-11 efficiently activated IL-11+ colonic fibroblasts and colon tumor organoids. Transcriptome analysis showed that IL-11+ fibroblasts expressed genes associated with tissue repair and cell proliferation. Thus, IL-11+ fibroblasts produce several growth factors that induce the proliferation of nearby tumor cells. Moreover, the expression levels of some of the genes enriched in IL-11+ fibroblasts were elevated in stromal tissues in human CRC, and this high expression was associated with reduced recurrence-free survival duration in human CRC. Thus, our results suggest that IL-11+ fibroblasts activate both colon tumor epithelial cells and colon fibroblasts through IL-11 secretion, thereby contributing to tumor progression.
The newly developed Il11-Egfp reporter mice enabled us to characterize the IL-11+ fibroblasts that appeared in mouse models of colitis and CAC. In the colitis model, IL-11+ fibroblasts exclusively expressed stromal cell markers, such as Thy1 and podoplanin. A recent single-cell RNA-seq analysis of colon biopsies from healthy individuals and UC patients revealed that colon samples from UC patients exhibited a unique subset of fibroblasts, termed IAFs9. IAFs express IL11, IL24, IL13RA2, and TNFSFR11B, which were also elevated in IL-11+ fibroblasts. However, large numbers of genes enriched in IL-11+ fibroblasts were not expressed in IAFs, suggesting that IL-11+ fibroblasts and IAFs might be different populations.
In contrast to the results in DSS-induced colitis, we detected a few IL-11+ cells expressing epithelial cell markers, such as EpCAM and E-cadherin, in tumor tissues. Previous studies have reported that IL-11+ cells are derived from stromal or epithelial cells17,24. Our present results revealed that IL-11+, EpCAM+, and E-cadherin+ epithelial cells might be tumor cells themselves. A previous study has also reported that tumor cells, such as breast cancer or colon cancer cells, produce IL-1138. Future scRNA-seq analysis will further characterize heterogeneous populations of IL-11+ cells in the tumor microenvironment.
Elucidation of the mechanisms underlying IL-11 production by fibroblasts in the tumor microenvironment may be crucial for understanding how tumor cells instruct stromal cells. Previous studies have demonstrated that TGFβ induces IL-11 upregulation in various cell types20,21. Indeed, we found that TGFβ stimulation-induced IL-11 production by colonic fibroblasts. Moreover, in murine xenograft models, human tumor cell lines that ectopically express human TGFβ1 can elicit IL-11+ CAFs24. However, in our present study, anti-TGFβ antibody treatment did not downregulate Il11 expression in colonic adenomas of Apcmin/+ mice or in AOM/DSS-induced CAC. Overall, although TGFβ per se was able to induce IL-11 production, TGFβ may not be involved in the induction of IL-11+ fibroblasts in the present tumor models, including AOM/DSS-induced CAC and colon adenoma in ApcMin/+ mice. On the other hand, blockade of the MEK/ERK pathway by trametinib attenuated Il11 expression in mouse colon in DSS-induced colitis, AOM/DSS-induced CAC, and colon adenoma in ApcMin/+ mice. More importantly, blockade of the MEK/ERK pathway reduced proliferation and increased apoptosis of tumor cells in these tumor models. Given that IL-11 released from IL-11+ fibroblasts activated the MEK/ERK pathway in tumor cells, IL-11 and the MEK/ERK pathway may constitute the feed-forward loop via cancer-associated IL-11+ fibroblasts and tumor cells. It is reasonable to speculate that one of the mechanisms how trametinib inhibited proliferation and induced apoptosis of tumor cells would be caused by the shutoff of this feed-forward loop.
Previous studies have shown that IL-11 and IL-22 induce the proliferation and cell survival of colonic epithelial cells through STAT3 activation15,35. Indeed, under our experimental conditions in colonic epithelial organoids, IL-22 induced strong STAT3 phosphorylation, whereas IL-11 induced only weak STAT3 phosphorylation. In sharp contrast, IL-11 induced robust phosphorylation of STAT3 in colonic fibroblasts. Intriguingly, the expression of Il11ra in colon tumor organoids was higher than in colon epithelial organoids, suggesting that colon tumor cells can efficiently respond to IL-11 stimulation as the tumor develops. qPCR analysis revealed that the expression of Il11ra did not differ between IL-11+ and IL-11− fibroblasts. Thus, it appears that colonic fibroblasts produced IL-11 in response to factors from tumor cells, which, in turn, activated and induced STAT3 phosphorylation in both IL-11+ and IL-11− colonic fibroblasts in an autocrine or paracrine manner. This feed-forward loop between fibroblasts and tumor cells via secreted IL-11 from IL-11+ fibroblasts might contribute to tumor progression. Although ColVI+ fibroblasts and IL-11+ fibroblasts appear to promote tumor progression10, global gene expression profiles in these two populations were different. It is currently unclear whether these two-cell populations are derived from different cell lineages or represent different activation stages. Further study will be required to address this issue.
CAC development was attenuated in Il11ra1−/− and Il11−/− mice treated with AOM/DSS, but deletion of these genes did not dramatically affect tumor development compared with those tumors in a previous study17. The reason for these discrepancies is unknown. However, the genetic background of the mice (C57/BL6 vs. 129/C57/BL6 mixed background) might affect the tumor cells’ dependence on IL-11 signaling. On the other hand, our transcriptome analysis revealed that IL-11+ fibroblasts expressed various genes associated with tissue repair and cell proliferation. Indeed, we found that high expression of a set of genes in IL11FS, but not IL11 or signature genes of IAFs (IL11/IL24/IL13A2/TNFRSF11B), was associated with reduced recurrence-free survival duration in CRC patients. A previous study reported that high expression of IL11-responsive signature (IL11RS) genes induced in a human colon cancer cell line stimulated with IL-11 is correlated with reduced recurrence-free survival duration in CRC patients24. Given that IL11FS and IL11RS might be different, IL-11 activates both fibroblasts and tumor cells, thereby contributing to CRC progression. Thus, IL-11+ fibroblasts are potential targets in the treatment of CRC.
Azoxymethane (A5486, Sigma-Aldrich), murine IL-11 (418-ML-025, R&D), human IL-11 (418-ML-025, R&D), murine IL-22 (576202, BioLegend), NAC (11568-92, Nakalai), mouse TGFβ1 (763102, BioLegend), and trametinib (T-8123, LC Laboratories) were purchased from the indicated sources. The following antibodies used in this study were obtained from the indicated sources: anti-β-actin (622102, BioLegend, 1:1000), anti-BrdU (BU1/75, BIO-RAD, 1:100), anti-CD45 (13917, CST, 1:200), anti-cleaved caspase-3 (Asp175) (9664, CST, 1:2000), anti-collagen I (ab34710, Abcam, 1:500), anti-collagen IV (ab6586, Abcam, 1:500), anti-E-cadherin (560062, BD Biosciences, 1:200), anti-phospho-ERK (4370, CST, 1:800 for IHC, 1:1000 for Western blotting), anti-ERK (9102, CST, 1:1000), anti-GFP (GFP-Go-Af1480 or GFP-Rb-Af2020, Frontier Institute, 1:200), anti-human IL-11 (LS-C408373, LSBio, 1:500), anti-mouse IL-11 (in house, final 750 ng/ml)32, anti-Ki67 (ab16667, Abcam, 1:100), anti-podoplanin (127403, BioLegend, 1:100), anti-α-SMA (ab5694, Abcam, 1:200), anti-phospho-STAT3 (9145, CST, 1:1000), anti-STAT3 (SC-482, Santa Cruz, 1:1000), anti-tubulin (T5168, Sigma-Aldrich, 1:50,000), anti-vimentin (9856, CST, 1:200), and anti-Wnt5a/b (C27E8, CST, 1:50). Anti-horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (NA934, 1:5000) and anti-mouse IgG (NA931, 1:5000) antibodies were from GE Healthcare. Alexa Fluor 488-conjugated donkey anti-rabbit IgG (A21206, 1:500), Alexa Fluor 594-conjugated donkey anti-rabbit IgG (A21207, 1:500), Alexa Fluor Plus 594-conjugated donkey anti-rabbit IgG (A32754, 1:500), Alexa Fluor 647-conjugated donkey anti-rabbit IgG (A31573, 1:500), and Alexa Fluor 488-conjugated donkey anti-goat IgG (A11055, 1:500) antibodies, and Alexa Fluor 594-conjugated streptavidin (S11227, 1:500) were purchased from Invitrogen. ImmPRESS® VR anti-rabbit IgG HRP polymer detection kit (MP-6401, Vector Laboratories, 1:1) and biotinylated goat anti-Rabbit Immunoglobulins (E0432, Dako, 1:200) were purchased from the indicated sources.
Unless otherwise indicated, the following antibodies used for flow cytometry were obtained from TONBO Biosciences; anti-CD11b (20-0112, clone M1/70, 1:100), anti-CD16/CD32-mAb (2.4G2) (made in house, final 0.01 mg/ml), anti-CD24a (101813, BioLegend, clone M1/69, 1:100), anti-CD29 (102207, BioLegend, HMβ1-1, 1:100), anti-CD31 (17-0311-82, eBioscience, clone 390, 1:250), anti-CD34 (e13-0341-81, eBioscience, clone RAM34, 1:100), anti-CD45.1 (35-0453, clone A20, 1:100), anti-CD45.2 (20-0454, clone 104, 1:100), anti-EpCAM (118214, BioLegend, clone G8.8, 1:250), anti-ICAM-1 (561605, BD Biosciences, clone 3E2, 1:100), anti-Lyve1 (50-0443-80, eBioscience, clone ALY7, 1:100), anti-MHC Class II (130-102-139, Miltenyi Biotec, clone M5/114.15.2, 1:250), anti-PDGFRα (17-1401-81, eBioscience, clone APA5, 1:100), anti-podoplanin (127414, BioLegend, clone 8.1.1, 1:250), anti-Sca-1 (122512, BioLegend, clone E13161.7, 1:250), anti-TER-119 (116212, BioLegend, clone TER-119, 1:100), anti-Thy1.2 (20-0903, clone 30-H12, 1:250), anti-VCAM-1 (105718, BioLegend, clone 429, 1:100), and Streptavidin APC (17-4317-82, eBioscience, 1:500).
The hybridoma cell lines, 1D1139 and 2.4G2 that produce neutralizing antibody against all TGFβ isoforms (β1, β2, and β3) and antibody against mouse CD16/32, respectively, were purchased from ATCC. These antibodies were produced in house. Control mouse IgG (I5381) was purchased from Sigma-Aldrich.
All antibodies that came from commercial vendors are validated by the manufactures for the species and assay in our study. Validation data are available on the manufacture’s websites. All antibodies were initially tested against unstained controls and dilution series were performed to optimize.
Human colon cancer cell lines, HT29, and HCT116 cells were obtained from ATCC. A human breast cancer cell line, MDA-MB-231 cells were provided by T. Sakamoto. These cell lines were cultured in DMEM supplemented with 10% FBS. Cultrex® R-spondin1 (Rspo1) Cells were obtained from Trevigen.
Il11−/− mice (generated in our lab) and Il11ra1−/− mice (provided by L. Robb) were previously described32,40. Apcmin/+ (002020) were purchased from Jackson Lab. C57BL/6 (CD45.2+) and C57BL/6-SJL (CD45.1+) mice were purchased from Japan-SLC.
Mice were housed at 23 ± 2 °C, a humidity of 55 ± 5%, and a 12 hr dark/light cycle. Mice in different cages or derived from different sources were cohoused for 2 weeks to normalize the microbiota composition before experiments. All animals were housed and maintained under specific pathogen-free conditions in the animal facility at Juntendo University School of Medicine or Toho University School of Medicine. All experiments were performed according to the guidelines approved by the Institutional Animal Experiment Committee of Juntendo University School of Medicine or Toho University School of Medicine (19-51-414, 19-51-411).
Detailed information about mice, including genotypes, ages, and genders used in this study was described in Supplementary Table 2.
Generation of Il11-Egfp reporter mice
The Egfp reporter gene was introduced into the BAC clone (RP23-285B12) by two-step Red/ET recombineering technology according to the manufacturer’s protocol (Gene Bridges). In the first step, a rpsL-neo cassette included in the kit was amplified by PCR using a primer set (Il11-ET1-F2: ACTCCCTCAGACCCAGAGTTTGGCCTGATTTCTCCCTTCTGTCCACAGGTGGCCTGGTGATGATGGCGGGATCG and Il11-ET1-R2: ACGACTCTATCTGGCCAGAGGCTCAGCACCACCAGGACCAGGCGACAAACTCAGAAGAACTCGTCAAGAAGGCG) and inserted into the target region of the BAC clone. In a second step, the rpsL-neo cassette in the modified BAC clone was replaced with Egfp-polyA cassette, amplified from Egfp-expression vector (pAWZ) using a primer set (Il11-ET2-F2: ACTCCCTCAGACCCAGAGTTTGGCCTGATTTCTCCCTTCTGTCCACAGGTATGGTGAGCAAGGGCGAG and Il11-ET2-R2: ACGACTCTATCTGGCCAGAGGCTCAGCACCACCAGGACCAGGCGACAAACctCTAGTGGATCATTAACGCTTAC). A resultant clone designated as IL11-Egfp was verified by restriction digestion of BAC DNA and by sequencing.
Intracytoplasmic sperm injection (ICSI) was performed as previously described with slight modifications41. The mixture of sperm and Il11-Egfp DNA was diluted with Hepes-modified CZB containing 12% polyvinylpyrrolidone (Sigma-Aldrich) before being used for ICSI. Injections were performed by micromanipulators (Leica) with a PMM-150 FU piezo-impact drive unit (Prime Tech) using a blunt-ended mercury-containing injection pipette. After discarding the midpiece and tail, the head of spermatozoa was injected into an oocyte from C57/BL6 mice. Oocytes matured into two-cell stage embryos 24 h after injection, and then two-cell stage embryos were transferred to the oviducts of pseudopregnant females. Transgenic founders were backcrossed to C57/BL6J mice for several generations. One line exhibited an intimate correlation of Il11, and Egfp expressions were selected and used for further experiments.
Induction of DSS-induced colitis and colitis-associated cancer (CAC) in mice
Nine to fifteen-week-old male wild-type or Il11-Egfp reporter mice received 1.5% DSS (MW: 36,000–50,000 D; MP Biomedicals) ad libitum in drinking water for 5 days, which then was changed to regular water. To reduce gut commensal microflora, mice received mixtures of antibiotics in drinking water containing ampicillin (1 g/L, Sigma-Aldrich), kanamycin (0.4 g/L, Sigma-Aldrich), gentamicin (0.035 g/L, Sigma-Aldrich), metronidazole (0.215 g/L, Sigma-Aldrich), vancomycin (0.18 g/L, Sigma-Aldrich), and colistin (0.042 g/L, Sigma-Aldrich). Administration of antibiotics into mice started at 4 weeks before DSS treatment and continued during DSS treatment. To attenuate oxidative stress in DSS-treated mice, mice received NAC (10 g/L) along with DSS in drinking water for 5 days. To neutralize TGFβ in DSS-treated mice, mice were intraperitoneally injected with anti-TGFβ antibody (1D11) or control mouse IgGs (5 mg/kg) day 2 and day 4 after DSS treatment. To inhibit ERK activation in DSS-treated mice, a MEK inhibitor, trametinib (2 mg/kg), was administered into mice by gavage at 30 and 6 h before DSS treatment at a fine suspension in 0.5% Hydroxypropyl Cellulose (Alfa Aesar) and 0.2% Tween-80.
To test whether EGFP+ cells were proliferating in the colon of DSS-treated mice, we labeled proliferating cells in Il11-Egfp reporter mice by intraperitoneal BrdU injection (B5002, Sigma-Aldrich) (40 mg/kg) on day 6 after DSS treatment. Then, mice were killed at 24 hr after BrdU injection. Colonic sections were stained with anti-GFP and anti-BrdU antibodies.
To induce CAC, 9- to 15-week-old female mice were intraperitoneally injected with 10 mg/kg AOM (Sigma-Aldrich). One week later, mice received 1.5 % DSS ad libitum in drinking water for 5 days, followed by 2 weeks of regular water, and this was repeated for two additional cycles. To reduce numbers of commensal bacteria and oxidative stress in AOM/DSS-treated mice or Apcmin/+ mice, we administered mixtures of antibiotics and NAC into the indicated mice for the last 8 weeks and 4 weeks just before the sacrifice, respectively. Trametinib (2 mg/kg) (−6 and −30 h) or anti-TGFβ antibody (5 mg/kg) (on day −1, −3, −5) were administered into AOM/DSS-treated mice or Apcmin/+ mice at the indicated days just before sacrifice.
To isolate IL-11+ cells, the colon was removed from DSS-treated Il11-Egfp reporter mice. Then, the colon was minced with scissors and digested in RPMI 1640 containing 100 U/mL Penicillin and 100 μg/mL Streptomycin, 1 mg/mL Collagenase (Wako), 0.5 mg/mL DNase (Roche), 0.5 mg/mL Dispase (Roche), and 2% (v/v) fetal bovine serum (FBS, Gibco) for 60 min. Single-cell suspensions were prepared, and cells were stained with the indicated antibodies and analyzed by LSRFortessa X-20 (BD Biosciences) or BD Verse (BD Biosciences). Data were processed by FlowJo software Version 10.7.1 (FlowJo), BD FACSDiva Software Version 8.0.1 (BD Bioscience), and BD FACSuite Software Version 1.0 (BD Bioscience).
To isolate IL-11+ cells from tumors in the colon of Il11-Egfp reporter mice treated with AOM/DSS or Apcmin/+;Il11-Egfp mice, tumor tissues were removed from non-tumor tissues. Then, single-cell suspension from tumor tissues was prepared as described above. Cells were stained with the indicated antibodies, and the expression of various cell surface markers on EGFP+ cells was analyzed by flow cytometry.
Generation of BM chimeras
To test whether BM cells were differentiated into IL-11+ stromal cells in the tumor microenvironment, we isolated BM cells from Il11-Egfp reporter mice (CD45.2) and then transferred BM cells into 4- to 5-week-old recipient mice [C57BL/6-SJL mice (CD45.1)] that had been exposed to lethal irradiation (9.0 Gray). One month following reconstitution, BM transferred mice were subjected to AOM/DSS treatment.
For reciprocal BM transfer experiments, BM cells were prepared from Il11+/+ or Il11−/− mice (CD45.2). Then, 3–5 × 106 BM cells were transferred to 8-week-old recipient mice [C57BL/6-SJL mice (CD45.1)] that had been exposed to lethal irradiation (9.0 Gray). In reciprocal BM transfer experiments, BM cells from wild-type C57BL/6-SJL mice (CD45.1) were transferred to Il11+/+ or Il11−/− mice (CD45.2) that had been exposed to lethal irradiation (9.0 Gray).
At 2–3 months after the transfer, peripheral blood mononuclear cells were collected and stained with FITC-conjugated anti-CD45.1 and allophycocyanin (APC)-conjugated anti-CD45.2 antibodies. The chimerism of BM cells was calculated by counting numbers of CD45.1+ and CD45.2+ by flow cytometry. Average chimerisms were more than 90%.
Quantitative PCR (qPCR) assays
Total RNAs were extracted from the indicated tissues of mice by using TRI Reagent (Molecular Research Center) or Sepasol II Super (Nacalai Tesque), and cDNAs were synthesized with the RevertraAce qPCR RT Kit (Toyobo). To remove residual DSS, mRNAs prepared from the colon of mice treated with DSS were further purified by LiCl precipitation as described previously42. Quantitative polymerase chain reaction (qPCR) analysis was performed with the 7500 Real-Time PCR detection system with CYBR green method of the target genes and murine Hprt an internal control with 7500 SDS software 2.3 (Thermo Fisher Scientific). The primers used in this study are shown in Supplementary Table 3.
We compared gene expression profiles of RNAs from EGFP-positive and negative fibroblasts from the colon of Il11-Egfp reporter mice (n = 3 mice) on day 7 after DSS administration. To isolate EGFP+ and EGFP- cells by a cell sorter, colon tissues were minced with scissors and digested in RPMI1640 containing 0.25 mg/mL Liberase (Sigma), 50 μg/mL DNase (Roche), 100 U/mL Penicillin, 100 μg/mL Streptomycin, and 5% (v/v) fetal bovine serum (Gibco) for 60 min. EGFP+ and EGFP- cells among Ter119-CD45- CD31- EpCAM- cell populations were enriched using MojoSort Mouse anti-APC Nanobeads (BioLegend) and MojoSort Magnet (BioLegend) and sorted by BD FACSAriaTM III Cell Sorter (BD Biosciences). Total RNAs were subjected to RNA-seq analysis. We collected roughly 10,000 fibroblasts per each group, and purity of EGFP+ fibroblasts was ~90%. RNA-seq analyses were performed using the 5′Tag-seq method as described previously43. Briefly, polyA RNAs were trapped by oligo-dT-immobilized magnetic beads and reverse-transcribed by using Superscript IV (Thermo Fisher Scientific). Then, polyC tailing and 2nd strand synthesis were performed, and cDNA was amplified by PCR. Resulted cDNA products were converted to Ion Torrent sequencing libraries using NEBNext UltraII FS library prep kit (New England Biolabs). RNA sequencing was performed with Ion 540 Kit-Chef, Ion 540 Chip Kit, and Ion Genestudio S5 Sequencer (Thermo Fisher Scientific) according to the manufacturer’s instructions. Adapter trimming and quality filtering of resulting fastq files were performed by using Cutadapt-v1.1844. Trimmed reads were mapped to the Refseq mm10 RNA using Bowtie2-2.2.545 with the following parameters: t -p 16 –N 1 -D 200 –R 20 -L 20 -i S,1,0.50 -nofw. Tag numbers of each gene represented the expression level of each gene and were used as count data. Genes with tag number ≥10 were deemed low expressed and were excluded from the analysis. The sample to sample normalization was performed with R (version 3.5.1) and TCC package46. Normalized data were then tested for differential gene expression using the TCC package, which integrates the edgeR package47. Genes with adjusted P < 0.05, fold-change >2 were identified as statistically significant differentially expressed genes. GO enrichment analysis of differentially expressed genes were performed using the DAVID Bioinformatics Resources (https://david.ncifcrf.gov/home.jsp). Data were deposited in NCBI as a GEO accession number GSE141644 and GSE164232.
To identify target genes by IL-11 in the colon, we intravenously injected 10 μg of IL-11R agonist (provided by K. Tsumoto) into wild-type mice (n = 3 mice). IL-11R agonist is a modified version of human IL-11, where the mutations were introduced into the linker region of human IL-11 to increase stability and biological activities to 10 fold higher than the original IL-11. The detailed characterization was described elsewhere48. Mice were sacrificed at 3 h after injection. Total RNAs were extracted from the colon of mice by using Sepasol II Super. Labeled cRNAs were prepared from total RNA using the Agilent’s Quick Amp Labeling Kit (Agilent). Following fragmentation, cRNA were hybridized to SurePrint G3 Mouse Gene Expression 8x60K (Agilent) according to the manufacturer’s instruction. Raw data were extracted using the software provided by Agilent Feature Extraction Software (v22.214.171.124). The raw data for the same gene were then summarized automatically in Agilent feature extraction protocol to generate raw data text file, providing expression data for each gene probed on the array. Array probes that have Flag A in samples were filtered out. The selected processed signal value was transformed by logarithm and normalized by quantile method. Statistical significance of the expression data was determined using fold change and local-pooled-error test49 in which the null hypothesis was that no difference exists among two groups. Hierarchical cluster analysis was performed using complete linkage and Euclidean distance as a measure of similarity. Gene-Enrichment and Functional Annotation analysis for significant probe list was performed using Gene ontology (http://geneontology.org). All data analysis and visualization of differentially expressed genes was conducted using R 3.0.2 (www.r-project.org). Data were deposited in NCBI as a GEO accession number GSE141643 and GSE141644.
For comparing enriched genes in IL-11+ fibroblasts and IAFs, we used Gene Set Enrichment Analysis (GSEA) software (version 4.1, Broad Institute) and p-value was calculated by two-tailed Kolmogorov-Smirnov test50,51.
Tissues were fixed in 10% formalin and embedded in paraffin blocks. Paraffin-embedded colonic sections were used for H&E staining, immunohistochemical, and immunofluorescence analyses. For IHC, paraffin-embedded sections were treated with Instant Citrate Buffer Solution (RM-102C, LSI Medicine) or Target Retrieval Solution (S1699, Dako) appropriate to retrieve antigen. Then tissue sections were stained with the indicated antibodies, followed by visualization of Alexa-conjugated secondary antibodies or biotin-conjugated secondary antibodies followed by Streptavidin-HRP (Vector Laboratories).
In tumor samples, tissue sections were preincubated with MaxBlockTM Autofluorescence Reducing Kit (MaxVision Biosciences) according to the manufacturer’s instructions. After blocking, tissue sections were stained with the indicated antibodies as described above.
Pictures were obtained with an all-in-one microscope (BZ-X700, Keyence) or BX-63 (Olympus) and analyzed with BZ-X Analyzer (Keyence) or cellSens (Olympus) software. Positive areas and signaling intensities (for IL-11 staining) for the indicated antibodies and respective total areas were automatically calculated using Hybrid Cell Count (Keyence). Confocal microscopy was performed on an LSM 880 (Zeiss) or A1R (Nikon). Images were processed and analyzed using the ZEN software (Zeiss) or the NIS-Elements (Nikon) or an image-processing package, Fiji (https://fiji.sc/).
Organoid culture and transplantation of tumor organoids
Mouse colon epithelial and tumor organoids were established from isolated crypts of wild-type mice and mutant mice carrying a truncated Apc gene (Apcdelta716) as previously described52. Obtained colonic organoids were cultured in Advanced DMEM/F12 (Thermo Fisher Scientific) containing 10 mM HEPES (Thermo Fisher Scientific), 1 x GlutaMAX (Thermo Fisher Scientific), 1 x B27 (Thermo Fisher Scientific), NAC (1 μM), murine epidermal growth factor (50 ng/mL, Thermo Fisher Scientific), murine Noggin (100 ng/mL, Peprotech), 0.5 mM A83-01 (Tocris), 3 μM SB202190 (Sigma), 1 μM nicotinamide (Sigma), Afamin and Wnt3A-condition medium (CM) (final concentration of 50%) which was provided by J. Takagi53 and R-spondin 1-CM (final concentration of 10%) (Trevigen). Colon epithelial organoids from wild-type (WT) and Apcdelta716 mice were stimulated with IL-11 (100 ng/mL) or IL-22 (100 ng/mL) for 30 min unless otherwise indicated. Total and phosphorylated STAT3 were analyzed by Western blotting.
The small intestinal tumor organoids from villin-CreER-Apcdelta716-Kras+/LSL-G12D-Tgfbr2flox/flox-Tp53+/LSL-R270H (AKTP) mice were described previously34. AKTP organoids were cultured in Advanced DMEM/F12 containing 10 mM HEPES, 1 x GlutaMAX, 1 x B27, NAC (1 μM), murine epidermal growth factor (50 ng/mL), murine Noggin (100 ng/mL). For transplantation, AKTP organoids were mechanically dissociated, and 3 × 105 organoid cells mixed in Matrigel were injected into the subepithelial tissues of the rectum of Il11-Egfp reporter mice. At five weeks after transplantation, tumors were removed and subjected to histological analysis.
AKTP organoids, HT29, and HCT116 cells were stimulated with murine or human IL-11 (100 ng/mL) for 30 min. Total and phosphorylated STAT3 were analyzed by Western blotting.
Isolation and stimulation of colonic fibroblasts
To isolate colonic fibroblasts, single-cell suspensions were prepared as described above and cultured in DMEM containing 10% FBS, 1% GlutaMAX (Thermo Fisher Scientific), 10 mM HEPES, 1% MEM Non-Essential Amino Acids Solution (100×) (Nacalai Tesque), 100 U/mL Penicillin, 100 μg/mL Streptomycin, and 2.5 μg/mL of Amphotericin B (Sigma). The culture medium was changed every day until colonic fibroblasts started to grow spontaneously. Colonic fibroblasts (5 × 105) were unstimulated or stimulated with mouse TGFβ1 (100 ng/mL) for 16 h. Concentrations of murine IL-11 in the culture supernatants were determined by ELISA according to the manufacturers’ instruction (R&D Systems).
To detect phosphorylation of STAT3, colonic fibroblasts were stimulated with IL-11 (100 ng/mL) for 30 min. Total and phosphorylated STAT3 were analyzed by Western blotting.
Cells were lysed in a RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM PMSF, 1 μg/ml aprotinin, and 1 μg/ml leupeptin). After centrifugation, cell lysates were subjected to SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore). To detect IL-11, cell lysates were subjected to SDS-PAGE under non-reducing conditions. The membranes were immunoblotted with the indicated antibodies. The membranes were developed with Super Signal West Dura extended duration substrate (Thermo Scientific) and analyzed by Amersham Biosciences imager 600 (GE Healthcare). In some experiments, blots were quantified using the freeware program Fiji.
Comparison between the enriched genes in IL-11+ fibroblasts and in the genes in IL-11-stimulated ColVI+ colon fibroblasts
The publicly available data set (E-MTAB-7764) was obtained from ArrayExpress database (www.ebi.ac.uk/arrayexpress). FASTQ files were pre-processed by the Fastp 0.20.1 (https://github.com/OpenGene/fastp), then they were quantified with Salmon algorithm 0.8.0 (https://github.com/COMBINE-lab/salmon). Analysis of differential gene expression was performed using DESeq2 1.14.1 with the following parameters: test: Wald; fitType: parametric. Genes with adjusted p < 0.01, fold change >2 were identified as statistically significant differentially expressed genes.
Comparison of the expression of enriched genes in IL-11+ fibroblasts between normal human mucosa and colon cancer tissues
The publicly available data set (GSE33113) was obtained from the Gene Expression Omnibus (GEO). This data set contains gene expression data from 90 colon cancer patients and six healthy persons. The expression data of enriched genes in IL-11+ fibroblasts was retrieved from the data set (GSE33113), and their signaling intensities of each gene in normal mucosa and colon cancer tissues were compared.
Comparison of the expression of enriched genes in IL-11+ fibroblasts between epithelium and stroma compartments in human colon cancer tissues
The publicly available data set (GSE35602) was obtained from the GEO. This data set contains expression profiling data from 13 CRC tissues were micro-dissected using Laser Microdissection System (Leica Microsystems). The expression data of enriched genes in IL-11+ fibroblasts was retrieved from the data set (GSE35602), and their signaling intensities of each gene in tumor stroma compartments and tumor epithelium compartments were compared.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of murine IL-11 in the culture supernatants were determined by ELISA according to the manufacturers’ instruction (R&D Systems).
Knockdown of Il11 by siRNAs
A human breast cancer cell line, MDA-MB-231 cells were provided by T. Sakamoto. MDA-MB-231 cells were maintained in DMEM containing 10% FBS. MDA-MB-231 cells were transfected with control or Il11 siRNAs using Lipofectamine 2000 (Invitrogen) at a final concentration of 50 nM. At 36 h after transfection, knockdown efficiency of IL-11 by siRNAs was analyzed by immunoblotting with anti-IL-11 antibody using cell lysates. Stealth RNAiTM siRNAs Negative Control, Med GC and human Il11, NM_000641.3 (HSS179893, HSS179894, HSS179895) were purchased from Thermo Fisher Scientific.
Human CRC tissues
Human colon tumors and adjacent normal tissues were obtained from Toho University Omori Medical Center. Colon tumors included 11 cases of adenomas, 10 cases of early cancers, and 10 cases of advanced cancers. Detailed clinical information is included in Supplementary Table 1. Histological assessment of adenomas and adenocarcinomas was according to the guidelines of the World Health Organization54. Early and advanced colon cancers were determined according to the TNM criteria (pT1, early cancer; pT2-4, advanced cancers)55. The present study was designed as a retrospective study and was approved by the Ethics Committee of Toho University School of Medicine (A16111). The need for informed consent was waived by the Ethics Committee.
Three publicly available data sets (GSE14333, GSE17536, and GSE17537) were obtained from the GEO. These data sets contain gene expression data and disease-free survival information from 232 primary CRC patients. Based on the expression patterns of IL11, a combination of IL11/IL24/IL13A2/TNFRSF11B, or IL11FS, we classified patients into two respective clusters using the hierarchical clustering method. The recurrence-free duration of each group was calculated using the Kaplan–Meier method. Statistical significance was analyzed by Mantel-Cox log-rank test. The hierarchical cluster analysis was performed using Ward’s method and Euclidean distance as a measure of similarity. All data analysis and visualization of differentially expressed genes was conducted using R 4.0.2 (www.r-project.org). Statical analyses were conducted with the following packages: MASS 126.96.36.199, stats 3.6.1, ggplot2 3.2.1 and BiocManager 1.30.10.
Statistical significance was determined by the unpaired two-tailed Student’s t-test, two-tailed Mann–Whitney U test, two-way ANOVA with Tukey’s multiple comparison test, one-way ANOVA with Tukey’s multiple comparison test, two-tailed Kolmogorov-Smirnov test (for GSEA), two-tailed local-pooled-error test (for microarray analysis), or two-tailed Mantel-Cox log-rank test as indicated. *P < 0.05 was considered to be statistically significant. All statistical analysis was performed with Graph Pad Prism 7 software (GraphPad Software).
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The RNA-seq and microarray data generated in this study have been deposited in the NCBI database under accession code GEO accession numbers GSE141643, GSE141644, and GSE164232. The microarray data used in this study are available in the NCBI database under accession code GEO accession numbers GSE14333, GSE17536, GSE17537, GSE35602, GSE33113. The RNA-seq data used in this study are available in the EMBL-EBI database under accession code number E-MTAB-7764. Source data are provided with this paper.
Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141–153 (2014).
Leoni, G., Neumann, P. A., Sumagin, R., Denning, T. L. & Nusrat, A. Wound repair: role of immune-epithelial interactions. Mucosal Immunol. 8, 959–968 (2015).
Kurashima, Y. & Kiyono, H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev. Immunol. 35, 119–147 (2017).
Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X. & Mifflin, R. C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73, 213–237 (2011).
Nowarski, R., Jackson, R. & Flavell, R. A. The stromal intervention: regulation of immunity and inflammation at the epithelial-mesenchymal barrier. Cell 168, 362–375 (2017).
Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312–319 (2015).
Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320–329 (2015).
Koliaraki, V., Pallangyo, C. K., Greten, F. R. & Kollias, G. Mesenchymal cells in colon cancer. Gastroenterology 152, 964–979 (2017).
Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730.e722 (2019).
Heichler, C. et al. STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut 69, 1269–1282 (2019).
Putoczki, T. & Ernst, M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109–1117 (2010).
Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773–789 (2018).
West, N. R. Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front. Immunol. 10, 1093 (2019).
Gibson, D. L. et al. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139, 1277–1288 (2010).
Kiessling, S. et al. Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J. Biol. Chem. 279, 10304–10315 (2004).
Yoshizaki, A. et al. Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells. Int. J. Oncol. 29, 869–876 (2006).
Putoczki, T. L. et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24, 257–271 (2013).
Molet, S. et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 108, 430–438 (2001).
Andoh, A. et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129, 969–984 (2005).
Bamba, S. et al. Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G529–G538 (2003).
Tang, W., Yang, L., Yang, Y. C., Leng, S. X. & Elias, J. A. Transforming growth factor-beta stimulates interleukin-11 transcription via complex activating protein-1-dependent pathways. J. Biol. Chem. 273, 5506–5513 (1998).
Nishina, T. et al. Interleukin-11 links oxidative stress and compensatory proliferation. Sci. Signal 5, ra5 (2012).
Nishina, T. et al. Critical contribution of nuclear factor erythroid 2-related factor 2 (NRF2) to electrophile-induced interleukin-11 production. J. Biol. Chem. 292, 205–216 (2017).
Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571–584 (2012).
Zhang, X. et al. IL-11 induces Th17 cell responses in patients with early relapsing-remitting multiple sclerosis. J. Immunol. 194, 5139–5149 (2015).
Yuan, J. H. et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25, 666–681 (2014).
Putoczki, T. L. & Ernst, M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy 7, 441–453 (2015).
Strikoudis, A. et al. Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells. Cell Rep. 27, 3709–3723.e3705 (2019).
Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110–115 (2017).
Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2, 1998–2004 (2007).
Tanaka, T. et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94, 965–973 (2003).
Deguchi, Y. et al. Generation of and characterization of anti-IL-11 antibodies using newly established Il11-deficient mice. Biochem. Biophys. Res. Commun. 505, 453–459 (2018).
Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the Apc gene. Science 256, 668–670 (1992).
Sakai, E. et al. Combined mutation of Apc, Kras, and Tgfbr2 effectively drives metastasis of intestinal cancer. Cancer Res. 78, 1334–1346 (2018).
Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465–1472 (2009).
Oshima, M. et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl Acad. Sci. USA 92, 4482–4486 (1995).
Lacroix, M., Siwek, B., Marie, P. J. & Body, J. J. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett. 127, 29–35 (1998).
Kitamura, H., Onodera, Y., Murakami, S., Suzuki, T. & Motohashi, H. IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. Oncogene 36, 6315–6324 (2017).
Dasch, J. R., Pace, D. R., Waegell, W., Inenaga, D. & Ellingsworth, L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J. Immunol. 142, 1536–1541 (1989).
Nandurkar, H. H. et al. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 90, 2148–2159 (1997).
Kimura, Y. & Yanagimachi, R. Intracytoplasmic sperm injection in the mouse. Biol. Reprod. 52, 709–720 (1995).
Viennois, E., Chen, F., Laroui, H., Baker, M. T. & Merlin, D. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res. Notes 6, 360 (2013).
Shichino, S. et al. Transcriptome network analysis identifies protective role of the LXR/SREBP-1c axis in murine pulmonary fibrosis. JCI Insight 4, (2019).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet 17, 10–12 (2011).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Sun, J., Nishiyama, T., Shimizu, K. & Kadota, K. TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinforma. 14, 219 (2013).
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Yanaka, S. et al. Non-core region modulates interleukin-11 signaling activity: generation of agonist and antagonist variants. J. Biol. Chem. 286, 8085–8093 (2011).
Jain, N. et al. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 19, 1945–1951 (2003).
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
Mihara, E. et al. Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/alpha-albumin. Elife 5, e11621 (2016).
Aaltonen, L. A., Hamilton, S. R., World Health Organization & International Agency for Research on Cancer. Pathology and Genetics of Tumours of the Digestive System. (IARC Press; Oxford University Press, distributor, 2000).
Sobin L. H., Gospodarowicz M. K. & Wittekind C. International Union against Cancer. TNM Classification of Malignant Tumours, 7th edn. (Wiley-Blackwell, 2010).
We thank L. Robb for Il11ra1−/− mice, K. Asano and M. Tanaka for the generation of anti-mouse IL-11 antibody, M. Ohmuraya, K. Araki and T. Yamamoto for the generation of Il11−/− mice, K. Tsumoto for IL-11R agonist, T. Sakamoto for MDA-MB-231 cells, K. J. Takagi for Afamin- and Wnt3A-conditioned medium, and J. Yasuda for assistance with RNA-seq analysis. We also thank Y. Kurashima, H. Kiyono, T. Sato, M. Kikkawa, M. Aoki, A. Nakajima, E. Tosti, and L.S. Lopez for technical advice. This work was supported in part by Grants-in-Aid for Scientific Research (B) 20H03475 (to H.N.); Grants-in-Aid for Scientific Research (C) 19K07391 (to T.N.) from the Japan Society for the Promotion of Science (JSPS); the Japan Agency for Medical Research and Development (AMED) through AMED-CREST (JP20gm1210002, to H.N.); the Private University Research Branding Project (to T.M. and H.N.) from the MEXT (Ministry of Education, Culture, Sports, Science and Technology), Japan; Toho University Grant for Research Initiative Program (TUGRIP) from Toho University (to H.N.); Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University (to M.N., M.O., H.N., and T.N.); the Project Research Grant of Initiative for Realizing Diversity in the Research Environment, Toho University (to T.N.), and research grants from the Uehara Memorial Foundation (to T.N.) and the Takeda Science Foundation (to T.N.).
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer review reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Nishina, T., Deguchi, Y., Ohshima, D. et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat Commun 12, 2281 (2021). https://doi.org/10.1038/s41467-021-22450-3
This article is cited by
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Nature Medicine (2023)
The past, present, and future of immunotherapy for colorectal cancer
Medical Oncology (2023)
Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
Molecular Medicine (2021)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.